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Dendritic cellMultiple sclerosis (MS) is a debilitating T cell mediated autoimmune disease of the central nervous system
(CNS). Animal models of MS, such as experimental autoimmune encephalomyelitis (EAE) and Theiler's
murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) have given light to cellular
mechanisms involved in the initiation and progression of this organ-speciﬁc autoimmune disease. Within the
CNS, antigen presenting cells (APC) such as microglia and astrocytes participate as ﬁrst line defenders against
infections or inﬂammation. However, during chronic inﬂammation they can participate in perpetuating the
self-destructive environment by secretion of inﬂammatory factors and/or presentation of myelin epitopes to
autoreactive T cells. Dendritic cells (DC) are also participants in the presentation of antigen to T cells, even
within the CNS. While the APCs alone are not solely responsible for mediating the destruction to the myelin
sheath, they are critical players in perpetuating the inﬂammatory milieu. This review will highlight relevant
studies which have provided insight to the roles played by microglia, DCs and astrocytes in the context of
CNS autoimmunity.-Immunology, Feinberg School
. Tel.: +1 312 503 7674; fax:
iller).
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Multiple sclerosis (MS) is the most common idiopathic inﬂamma-
tory demyelinating disease of the central nervous system (CNS)
affecting roughly 0.1% of the worldwide population, primarily young
adults in North America and Europe [1]. MS is driven bymyelin-speciﬁc
autoreactive T cells that inﬁltrate the CNS andmediate an inﬂammatory
response that results in demyelination and axon degradation [1–3].
Myelin is an extension of oligodendrocytes, whichwraps tightly around
the axon of a neuron, providing insulation for fast electrical conduction
[3,4]. In the absence of myelin, neurons signal slowly or erroneously [4].
Demyelination manifests in such clinical symptoms as numbness,
muscle spasms, optic neuritis, and neuropathic pain. Current therapies
for MS non-speciﬁcally suppress the immune system to slow the
progression of disease. New immunomodulatory therapies that induce
myelin-speciﬁc T cell tolerance are currently being developed and
tested in clinical trials [5].
Antigen presenting cells (APCs) are necessary for the pathogenesis
of murine models of MS [6,7]. Upon encountering myelin antigen,
they mature and travel to lymph nodes where they present antigen to
naïve T cells [8,9]. T cell activation and survival require two signals
from APCs: antigen presentation by the major histocompatibilitycomplex [10] to the T cell receptor [11] and a secondary signal
provided by the interaction of co-stimulatory molecules such as CD80
and CD86with CD28 on T cells. During activation, T cell differentiation
into mature effector CD4+ T cell subsets (Th1, Th2, Th17, Treg)
depends on the cytokines produced by APCs [12]. Current data
suggests that MS is driven by both Th1 and Th17 subsets, although
each is mechanistically different [9,13]. Once activated, T cells trafﬁc
to the brain and cross the blood brain barrier (BBB). In the brain they
are re-stimulated by APCs [14], leading to disease induction and
progression. As disease progresses, new myelin antigens are pre-
sented by APCs (epitope spreading), leading to subsequent activation
of newly inﬁltrated T cells [15]. APCs are involved in multiple stages
during MS pathology, thus making them important cells to study and
possibly manipulate therapeutically. APC effector functions and
responses are commonly studied in vitro and within animal models
of MS.
There are currently two well-established mouse models of MS:
Theiler's murine encephalomyelitis virus-induced demyelinating
disease (TMEV-IDD) and experimental autoimmune encephalomy-
elitis (EAE) [16,17]. TMEV is a picornavirus that is an enteric pathogen
of mice and rats. Intracranial inoculation with TMEV in the IDD
susceptible (SJL/J) mouse strain, results in an ineffectual immune
response that limits viral titers, but does not completely clear the
virus. Inability to effectively clear the virus results in chronic viral
infection of the CNS leading to the induction of the myelin-speciﬁc T
cell mediated autoimmune disease. Clinically, a progressive course of
spastic hindlimb paralysis is evident in SJL/J mice beginning 4–
5 weeks following TMEV infection. This disease course is similar to
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virus family has been found to infect humans, thus potentially making
this mouse model even more clinically relevant [19].
EAE is the most extensively studied mouse model of MS [18], and
several of these studies have lead to current treatments for MS
patients [20]. It is an inducible CD4+ T cell mediated murine model of
MS that exhibits relapsing-remitting phases in SJL/J mice and chronic
progression in C57Bl/6 mice [21]. Disease is induced by immunization
with myelin peptide and an adjuvant or by adoptive transfer of CD4+
T cells isolated from immunized mice into naïve recipient animals.
Like TMEV-IDD, EAE is clinically characterized by ﬂaccid hindlimb and
tail paralysis.
Although these animal models of MS are different, APCs ultimately
have the same overall functions: antigen uptake, processing, and
presentation along with co-stimulatory molecule expression and
secretion of cytokines important for driving the proliferation and
differentiation of autoreactive effector T cell subsets [22]. Under-
standing the contribution of CNS inﬁltrating dendritic cells (DC) and
CNS-resident microglia and astrocytes to CNS autoimmune disease is
important for identifying possible therapeutic interventions. This
article will review research that addresses the functions of these APC
subsets known to be involved in MS, EAE, and TMEV-IDD pathology.
2. Macrophages and microglia
Perivascular macrophages (PVMs) are an abundant cell type in the
CNS, which can be distinguished frommicroglia based on their higher
levels of CD45 and MHC class II in both rodents and humans [23,24].
Anatomically, PVMs are large, round cells that are located between the
endothelial and glial basement membranes of cerebral blood vessels,
thus providing a strategic location to encounter pathogens and assist
in controlling innate and adaptive immune responses in the CNS [23].
Expression of MHC class II, CD80, CD86 and CD40 is highly
upregulated on PVMs during EAE and MS. Activation of PVMs is also
mediated by Th1-cytokines, IFNγ and TNFα [23]. Elimination of PVMs
using clodronate containing dichloromethylene diphoshonate
(Cl2MDP) liposomes in situ suppresses the clinical signs of EAE,
while the inﬂux of CD4+ T cells in the CNS is unaffected, suggesting
that macrophages are not critical for the inﬁltration of T cells in the
CNS [25,26]. These studies highlight a potential role for macrophages
in the development of CNS inﬂammation and demyelination.
Microglia are the bone marrow-derived resident macrophage of
the CNS. They are distinguished from peripheral macrophages by
lower level expression of CD45 [27]. Under resting conditions,
microglia constantly survey the CNS microenvironment, suggesting
that these cells are critical for maintaining CNS homeostasis [28–30].
Quiescent microglia express undetectable levels of MHC class I and II,
CD80, CD86, and CD40 [31]. However, in response to inﬂammatory
stimuli, microglia become activated and upregulate CD45, MHC and
co-stimulatory molecule expression, phagocytic ability, and obtain
the capacity to stimulate the proliferation of Th1 (IFN-γ-producing)
and Th2 (IL-4-producing) CD4+ T cell lines [27,32].
2.1. TLR expression and stimulation
Toll-like receptor (TLR) activation initiates effective induction of
pro-inﬂammatory cytokines and chemokines, type I interferons
(IFNs), and MHC and co-stimulatory molecules. All of which are
essential for initiating and propagating host inﬂammatory immune
responses [33]. The expression and functions of TLRs have been
extensively studied in the context of recognition of CNS pathogens
and autoimmunity. In response to TMEV infection, TLR 2, 3, 7, and 9
mRNA are signiﬁcantly upregulated in vitro and in situ [34–36].
Microglia possess constitutive and inducible expression of surface
receptors to recognize pathogens, which enable them to trigger and/
or amplify an inﬂammatory response in the CNS [27]. It is important tonote that expression patterns of TLRs in the CNS have been
extensively studied from puriﬁed cells in vitro.
Human microglia express robust levels of TLRs1–8 but low TLR9
levels, whereas primary murine neonatal microglia constitutively
express all TLRs in vitro. Microglia drastically upregulate several TLRs,
with TLR3 being the most signiﬁcantly detected, in response to direct
TMEV infection and IFN-γ in vitro [37–40]. Expression of TLR2 and
TLR3 is most abundant in MS tissue, however the cell type responsible
for the increased expression has yet to be determined [37].
Collectively, these studies suggest that microglia may serve as the
ﬁrst line in defense in the CNS by initiating potent pro-inﬂammatory
and antiviral responses against infectious pathogens. Using speciﬁc
knockout models, future studies need to be conducted to evaluate the
speciﬁc role of TLRs in microglia effector functions in the context of
CNS autoimmunity. For further information about the functions of TLR
signaling during CNS inﬂammation and autoimmunity, refer to
Carpentier et al. 2008 [41].
2.2. Cytokine production and responses
Due to their ubiquitous localization within the CNS, microglia are a
potent source of inﬂammatory cytokines and chemokines that are
essential for the initiation and propagation of a CNS immune
response. Microglia stimulated in vitro with IFN-γ, TLR stimuli, or
TMEV infection, increase expression of TNFα, IL-6, and IL-1β
[38,39,42]. Microglia also upregulate expression of type I IFNs in
response to innate stimuli and TMEV in vitro [38,40,43–45]. Highly
puriﬁed macrophages isolated from TMEV-infected mice at onset and
chronic induced demyelinating disease serve as potent APCs similarly
to microglia, however both cell types express comparable levels of
inﬂammatory cytokines, IL-6, IL-12p40, TNFα, and inducible nitric
oxide synthase (iNOS) [40]. In addition to these cytokines, microglia
cultured in vitro increase expression and production of IL-12p40, IL-
18, and IL-23p19, potent cytokines involved in Th1 and Th17 T cell
differentiation [38,40,46–50]. In active MS lesions, increased expres-
sion of IL-23p19 is also detected in microglia/macrophages [51].
Activated microglia in vitro also express high levels of iNOS and
produce high levels of nitric oxide (NO) in response to TLR stimuli,
pro-inﬂammatory cytokines, or direct TMEV infection [47,52–54].
Both puriﬁed microglia and macrophages from TMEV-infected brain
and spinal cord express high levels of iNOS mRNA [55], which could
lead to oligodendrocyte and myelin damage propagating demyelin-
ation. In acute MS lesions, iNOS is localized in macrophages, but
absent in chronic MS lesions [56]. Collectively, the production of
cytokines by both microglia and macrophages are critical for directing
the inﬂammatory environment within the CNS.
Although the functions of IFN-γ, TNF-α, and IL-12 have been
extensively studied in MS and its animal models, research efforts are
now focused on understanding how IL-17 and Th17 cells contribute to
the development and progression of MS and EAE. Th17 cells are
characterized by the production of IL-17A, IL-17F, and IL-22 [57]. The
differentiation of murine CD4+ T cells into Th17 cells is dependent on
signals from IL-6, tumor growth factor-beta (TGF-β) and IL-1; while
human CD4+ Th17 cells requires TGF-β in combinationwith IL-1β and
IL-6 or IL-23 [58,59]. IL-23 is required for the survival and
maintenance of these differentiated cells [57]. Microglia display
constitutive and inducible mRNA expression of IL-23p19, IL-12/
23p40, and IL-12p35, and their receptors, IL-23R and IL-12Rβ1 in
response to LPS or IFNγ in vitro [47]. During EAE, expression of IL-
23p19 in CNS CD11b+ cells (microglia, macrophages, and dendritic
cells) peaks early in disease, suggesting that expression of IL-23p19 by
these cells is critical for the initiation of CNS inﬂammation prior to
peripheral T cell inﬁltration [47].
Studies performed by Das Sarma et al., examined IL-17 and IL-17R
expressions in the CNS during EAE [60]. They demonstrated that IL-
17R is constitutively expressed in vivo in the CNS at very low levels,
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cellular source of IL-17R has yet to be determined in situ, however glial
cells may serve as a potential source for its expression during CNS
inﬂammation. Puriﬁed microglia in vitro constitutively express IL-
17RA mRNA, however express very low levels of IL-17R protein [60].
Despite low protein expression of IL-17R, microglia are capable of
efﬁciently responding to IL-17 stimulation, and how this relates to the
function of microglia in the induction and progression of disease has
yet to be determined.
2.3. T cell recruitment
Chemokine expression by microglia and macrophages is critical for
the recruitment of leukocytes to the CNS. Microglia cultured in vitro
increase expression of CCL2-5 and CXCL3 following stimulation with
TMEV [38,39,42]. Treatment with IL-17A stimulates signiﬁcant produc-
tion of CCL2, CCL12, CXCL1, and CXCL2 from both microglia and
astrocytes, suggesting a potential signaling cascade to regulate
chemokine expression during inﬂammatory, demyelinating disorders
[60]. The importanceof glial-produced chemokines inEAE ishighlighted
in a study byDoganet al. Bonemarrowchimeric andCCL2−/−micewere
used to further evaluate the signiﬁcance of glial-derived production of
CCL2. CNS–CCL2−/− mice develop signiﬁcantly reduced EAE disease
onset, progression, and demyelination, and had decreased levels of
iNOS- and TNFα-producing myeloid cDCs (CD11b+CD11c+) and
macrophages (CD11b+CD11c−) in the spinal cords of mice during
EAE. This demonstrates that CNS glial-produced CCL2 is required for the
recruitment of iNOS and TNFα-producing DCs and macrophages to
obtain optimal EAE disease [61]. InMS plaques, microglia/macrophages
in vivo are also signiﬁcant producers of CCL2, CCL3, CCL4, and CCL5
[62,63]. Thus, microglia and macrophages are important regulators of
recruiting inﬁltrating leukocytes into the CNS.
2.4. Antigen processing
Following activation, microglia are responsible for the removal of
cellular debris and pathogens during CNS injury, inﬂammation, and
infections, which can be correlated to antigen processing and
presentation to T cells [64]. Rodent and human microglia in vitro
phagocytize whole proteins and peptides of myelin [65,66]. Several in
vitro studies have shown that myelin phagocytosis by microglia and
macrophages triggers release of pro-inﬂammatory cytokines and
nitric oxide [66–68], suggesting that phagocytosis of myelin could
enhance neuroinﬂammation. Conversely, clearance of myelin debris is
necessary for remyelination, suggesting a dual role for microglial
phagocytosis [69].
2.5. T cell priming
To initiate T cell activation, APCs must deliver two signals: one
from antigenic peptides bound to MHC, and a second from a co-
stimulation signal. In the normal CNS, residentmicroglial cells express
negative or low levels of MHC molecules [64]. During TMEV-IDD and
EAE, microglia highly upregulate MHC I and II antigens in vitro and
ex vivo [38,40,44,55,70]. IL-17 in combination with IFN-γ upregulates
cell surface expression of MHC class II on microglia, however IL-17
alone has minimal effects, suggesting that there may be synergistic
effects between IL-17 and IFN-γ for initiating CD4+ T cell responses
and propagating inﬂammationwithin the CNS [71]. In MS brain tissue,
reactive microglia localized in active lesions had enhanced expression
of MHC class II molecules, HLA-DR, -DP, and -DQ [72]. Microglia
constitutively express low levels of CD80 and CD86 mRNA, but
expression is upregulated in response to inﬂammatory stimuli and
TMEV virus infection in vitro and ex vivo [38,40,53,65,66,73]. CD40
expression is upregulated on microglia following stimulation with
IFN-γ or TMEV in vitro and ex vivo [38,40,53,65,66,73]. CD40−/−microglia fail to become fully activated at peak EAE disease, which
correlates with a reduction in encephalitogenic T cells [74].
Microglia also present antigen to and activate CD4+ Th1 and CD8+ T
cells in response to direct inﬂammatory stimulation, indicating
microglia play a role in the activation of and/or cytotoxic cell lysis by
peripheral T cells inﬁltrating the CNS [31,38,40,75–77]. IFN-γ-activated
and TMEV-infected murine microglia are also capable of presenting
exogenous and endogenous myelin and viral peptides to CD4+ T cells
in vitro and ex vivo [31,38,44,77,78].
Potentially due to their lower expression of MHC class II, microglia
serve as poor activators of naïve T cells. For example, puriﬁed microglia
and macrophages isolated from mice with EAE are able to induce the
proliferation and IL-2productionof naïveCD4+Tcells howeveronly at a
relatively high APC:T cell ratio [6]. Rather, these cells may play a more
important role in the reactivation of T cells inﬁltrating into the CNS
during MS. These studies demonstrate that microglia increase expres-
sionof co-stimulatory andMHCmolecules and are capable of presenting
antigen to T cells more effectively compared to astrocytes, however less
efﬁciently than DCs [22,31].
2.6. Regulation
A number of regulatorymechanisms exist between T cells and APCs,
which elicit T cell dysfunction during autoimmunity and viral infections.
Programmed death receptor-1 and its ligands, programmed death-
ligand 1 (B7-H1/PD-L1) and programmed death-ligand 2 (B7-DC/PD-
L2) are integral players in inhibiting ongoing T cell responses [79].
Blocking the signaling between B7-H1:PD-1 helps restore “exhausted” T
responses, resulting in increased T cell function during viral infections
[80]. In the context of autoimmunity, inhibition of B7-H1:PD-1 signaling
has a detrimental effect due to the lack of control of autoreactive T cell
responses. B7-H1 expression in microglia is constitutive and inducible
by IFN-γ stimulation in vitro [81,82]. Additionally, CNS inﬁltrating
monocyte/macrophage/dendritic cells (CD11b+CD45hi) and CNS-resi-
dent microglia display enhanced expression of B7-H1 during remission
of EAE compared to acute phase of EAE, however both cell types lack
both constitutive and inducible expression of B7-DC [82]. Blockade of
B7-H1 on CNS inﬁltrating macrophages and microglia isolated from
micewithPLP139–151-induced EAE reducedCD4+T cell proliferation and
production of IFNγ and IL-17 ex vivo [81]. B7-H1 expression was found
in chronic active MS lesions [83]. Collectively, these studies identify a
novel interaction for the negative regulation ofmyelin-speciﬁc T cells by
both microglia and macrophages.
2.7. Requirement of microglia in EAE
Wehave provided several lines of evidence highlighting the function
of microglia in the initiation and regulation of the immune response
within the CNS. However, there are few studies that demonstrate the
requirement for microglia in EAE pathology. To determine the function
of microglia in vivo, Heppner et al. developed transgenic mice to
speciﬁcally ablate microglia using a system in which Herpes simplex
thymidine kinase expression was driven under the CD11b promoter
(CD11b-HSVTK) [84]. To ensure speciﬁcity bonemarrow chimeraswere
made such that only microglia expressed CD11b-HSVTK. Depletion of
microglia following treatment with gancyclovir (GCV) during EAE
resulted in reduced disease onset, progression, and demyelination.
Production of TNF-α, NO, and CCL4 was inhibited in brain slice cultures
in the presence of GCV in CD11b-HSVTK transgenic mice, suggesting
that microglial-derived inﬂammatory production of cytokines, chemo-
kines, and NO, promotes the recruitment and activation of leukocytes
into the inﬂamed CNS [84]. While results from this study demonstrated
the importance of microglia in contributing to disease severity, a direct
link for propagating T cell proliferation in vivo has yet to be
demonstrated due to the lack of technological advances.
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novel mechanism for their activation [85]. During ongoing PLP139–151-
induced EAE, antibodymediated depletion of ﬁbrin, a protein deposited
in the perivascular cuffs following BBB disruption, resulted in fewer
relapses compared to untreated mice. Additionally, immunization with
a speciﬁc ﬁbrinogen peptide, ﬁbrin γ377–395, prior to disease induction
resulted in a reduction in iNOS+ microglia, but had no effect on T cell
inﬁltration [85]. Upon ﬁbrin stimulation in vitro, anti-CD11b neutraliz-
ing antibody blocked microglial activation. Therefore, blockade of
ﬁbrinogen–CD11b interactions may be a potential therapeutic target
to inhibit microglial activation and suppress EAE disease.
In conclusion, bothmicroglia andmacrophages display awide range
of effector functions essential for controlling T cell responses which
contribute to the onset and progression of MS and its murine models.3. Dendritic cells
Dendritic cells are a class of bone marrow-derived cells, arising
from both myeloid and lymphoid progenitors. They are essential in
the coordination of both the innate and adaptive immune responses.
Classiﬁed as professional APCs, under steady state conditions their
distribution throughout tissue is diverse; they are present in
lymphoid and non-lymphoid tissue as well as in circulation [86].
Upon activation through TLR signaling or encounter with antigen
(Ag), DCs canmigrate from resident tissues or sites of inﬂammation to
the lymph nodes (LN) through their differential expression of
chemokine receptors including CCR7 [87,88]. Activation of DCs leads
to their maturation, where they express increased levels of MHC class
II as well as co-stimulatory markers (CD80, CD86, and CD40). These
modiﬁcations allow them to become efﬁcient at presenting cognate
Ag to naïve as well as memory T cells, which is critical for launching
the adaptive immune response.
DCs are a diverse cell type made up of several subsets. These are
classiﬁed by their expression of a variety of cell surface markers, as
well as possess various functional capacities. Two main subsets of DCs
are present in the steady state: conventional DCs (cDCs) and
plasmacytoid DCs (pDCs). Conventional DCs are identiﬁed by their
expression of the integrin CD11c and can express both CD11b and
CD45. They can be further subdivided into CD8+ and CD8− subsets.
Within the spleen cDCs are located in the marginal zones and T cell
areas, and are very efﬁcient at priming and promoting differential T
cells responses. pDCs are CD11cint and express the B cell marker B220.
PDCs produce large amounts of Type I interferons after viral infection
and are circulatory in nature, migrating to lymph nodes after
activation. However, they are less efﬁcient at priming T cell responses
than cDCs. For an extensive review on DC subsets and their
development, please see review by Wu and Liu [86].3.1. Ontogeny
The accumulation of DCs within the CNS [89–95] is noteworthy,
given the immunoprivileged nature of the CNS. Since the CNS has
resident APCs (microglia and astrocytes), inﬁltrating DCs may seem
excessive. Initially it was important to determine the origin of the DCs—
whether they were derived from CNS-resident precursors or whether
theywere indeed inﬁltrating from the periphery. It has been determined
that within the context of CNS inﬂammation, CD11c+ DCs are
preferentially derived from the bone marrow [9,96]. This was demon-
strated in studiesusingbonemarrowchimerasof congenicmice. In these
experiments, CD11c+ cells were shown to be derived from donor cells
(hematopoietic lineage) rather than the recipient (radioresistant) CNS
cells [7,9]. Thus, evidence indicates that CNS DCs accumulating during
inﬂammation are inﬁltrating rather than proliferating from CNS
precursors.3.2. Recruitment
The presence of DCs within the CNS is apparent, yet recruitment of
DCs to the CNShas not beenwell explored. In vitro studies usingprimary
cultures of brain microvascular endothelial cells (BMEC) showed
increased levels of DC transmigration with the addition of the
chemokine MIP-1α (CCL3). Migration by DCs across the BMECs was
facilitatedbyDCsecretedmatrixmetalloproteinase (MMP)9 [97]. Itwas
also demonstrated that migration of DCs also led to their maturation,
resulting in increased expression of co-stimulatory molecules. In these
experiments, MIP-1α appears to be involved in in vitro migration;
understanding the role of this chemokine should be veriﬁed in vivo.
Although migration of DCs within peripheral tissues has been well
studied,mechanisms of DC recruitment into the CNS and across the BBB
continue to be an area of ongoing research.
Localization studies of DCs in both mouse models and human MS
patients have provided clues to the function ofDCswithin the CNS. In the
inﬂamed tissue, DCs are found within inﬂammatory foci [91,94,98,99].
Interestingly, different subsets of DCs may preferentially home to
different regions of the brain. “Myeloid” cDCs (CD11c+CD11b+CD8−)
were found to clusterwith CD4+T cells in the perivascular inﬂammatory
foci [9,96]. Comparatively, macrophages were more marginalized [9].
This organization is reminiscent of secondary lymphoid tissue structure.
In addition, mDCs and macrophages were found throughout the
cerebellum and spinal cord, while pDCs accumulated more superﬁcially
in the cerebellar meningeal area [9].
Not only areDCs seen inmousemodels ofMS, but thepresenceofDCs
inMS lesions has also been demonstrated [100,101]. Seraﬁni et al. found
that both immature and mature (DC-SIGN+) DCs were present in the
meninges and parenchymal lesions of patients with both primary and
secondary progressive MS [101]. In non-inﬂamed tissue, DC-SIGN+ DCs
were found lining the blood vessels, suggesting they could be one of the
ﬁrst cells to encounter migrating T cells [7]. MDCs from the cerebral
spinal ﬂuid of patients with MS have been found to be more mature,
expressing higher levels of accessory molecules (HLA-DR, CD80, CD86
and CD40) [102] and also producing higher levels of the pro-
inﬂammatory cytokine IL-6 [103]. DCs that had engulfed MBP were
also found in close proximity to proliferating CD8+ T cells. In addition,
many of these DCs expressed CCR7, a chemokine receptor often
associated with maturation. Thus, it was concluded that immature DCs
are able to migrate to the CNS where they are able to mature as well as
present autoantigen to inﬁltrating T cells, thereby propagating the
autoreactive inﬂammation [101].
3.3. Antigen processing and presentation
Functionally, DCs are essential for priming both CD4+ and CD8+ T
cell responses. Upon their activation through TLR recognition, they are
capable of mediating Ag presentation as well as secreting cytokines
that can inﬂuence the developing adaptive response. For instance, in
viral settings, pDCs produce large amounts of type I IFNs, while CD8+
cDCs have been shown to secrete IL-12 and promote a Th1
environment [104]. Classically, T cell activation occurs in the LN
where DCs migrate after Ag uptake in peripheral tissues.
Though “mature”DCsaredetectable in the inﬂamedbrain, conﬂicting
results from early studies suggested CNS inﬁltrating DCs were very poor
T cell stimulators, or even suppressed T cell function [91,94,98]. We and
other groups have addressed these experimental questions and the data
indicates a strong role for DCs in CNS inﬂammation. Indeed, CD11c+DCs
are the only APC required for the initiation of adoptive transfer
EAE. Greter et al. used H2-Ab1 (MHC class II) knockout mice, where
H2-Ab1expression is drivenby theCD11cpromoter (CD11c-H2-Abi/H2-
Abi−/−). In this system MHC class II is exclusively restricted to CD11c+
DCs. Following adoptive transfer, mice were susceptible to EAE [7],
demonstrating thatCD11c+DCsaloneare sufﬁcient for thedevelopment
of disease.
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In a separate set of studies, mice were treated with Flt3L which binds
to a receptor on DCs inducing their expansion [105]. Mice treatedwith
Flt3L had increased numbers of DCs and greater disease score.
Inhibiting this signal with speciﬁc inhibitors reduced clinical signs of
disease [106]. The evidence that CD11c+ DCs are the only cell type
required for disease induction, and their increased numbers correlates
with increased disease, highlights the importance of these cells in
promoting CNS autoimmune pathology.
Within the CNS, it is likely that DCs are able to process and present
local Ag to inﬁltrating T cells. Evidence for this comes from our
previous studies which demonstrated that CNS inﬁltrating CD11c+
F4/80− DCs (“non myeloid”), along with macrophages, stimulated
naïve autoreactive T cells with or without the addition of exogenous
myelin peptide in both EAE as well as TMEV-IDD [6]. Indeed, the CNS
inﬁltrating DCs were the most efﬁcient at stimulating naïve T cells.
This demonstrates that DCsmigrating into the CNS are able to acquire,
process and present endogenous myelin proteins. Although this study
demonstrated the role of DCs in the propagation of the CNS
inﬂammation, it did not address their participation in initiation.
Clues to the initiationofmyelin-speciﬁc T cell activationbyDCs come
from several studies addressing the presence of myelin and neuroanti-
gen containing APCs in the cervical LNs (cLNs) in human MS patients
and both mouse and monkey models of EAE [107–110]. These studies
have demonstrated the presence of myelin antigen contained within
APCs in cLN of MS patients andmonkeys affected by EAE [107,108]. The
presence of myelin within the cLN was found to be speciﬁcally due to
demyelination. As well, APCs within the cLNs have been found to
contain neuroantigens, although, thesewere seen in patientswithMSas
well as healthy controls [110]. Although the CNS is considered an
immunopriveleged site, cLN are considered to be the “draining” lymph
nodes for the CNS. Interestingly, a recent study showed that myelin
debris and APCs containingmyelin are also present in themeninges and
perivascular spaces of MS patients. These DCs could potentially be
en route to the cLN where they could present Ag to T cells [109]. These
studies provide insight into the potential mechanism of the peripheral
priming of autoreactive T cells. Future studies should address the how
DCs migrate from the CNS into the cLN.
As previously discussed in this review, the role of Th17 cells during
MS has become newly appreciated. A study from our lab was the ﬁrst
to demonstrate that CNS “myeloid” (CD11c+CD11b+) DCs were able
to not only activate naïve PLP139 speciﬁc CD4+ T cells, but also
preferentially skewed them to differentiate into Th17 effectors [9].
Although mDCs resembled CD8+ DCs and pDCs with respect to
activation markers (MHC class II, CD80, and CD86), they were far
more efﬁcient at priming naïve T cell responses. In concordance with
CNS DCs “driving” a Th17 response upon stimulation with CD40, CNS
DCs have also been shown to produce the appropriate Th17 “driving”
cytokines: TGF-β, IL-6 and IL-23 [9,96]. Future studies should identify
signals that induce CNS inﬁltrating DCmediated T cell skewing so that
this may be exploited therapeutically.
It is clear that DCs indeed play a critical role in mouse models of
CNS inﬂammatory demyelinating disease as well as in MS. DCs are the
most efﬁcient APC population at priming naïve T cells. This property,
although normally beneﬁcial, becomes quite pathogenic in the
context of CNS autoimmune inﬂammation.
4. Astrocytes
Astrocytes are non-traditional brain-resident APCs. They are the
most abundant cell type of the brain and serve a variety of functions,
primarily unrelated to APC effector functions. Brieﬂy, they are
involved in maintaining the BBB, metabolizing glutamate, stabilizing
the extracellular concentration of potassium, and producing trophic
survival factors for neurons and other glia [111]. Astrocytes have a
star-like morphology and reside relatively stationary in both the grayand white matter of the CNS [111]. Astrocytes are not commonly
associated with immunological responses, but due to their abundance
in the CNS, their response to inﬂammation must be considered. It is
well accepted that their role in CNS immunity is largely regulatory
[112] while their contribution and capacity to present antigen and
activate T cells are still controversial.
4.1. TLR expression
Human and murine astrocytes only express one TLR constitutively,
TLR3,which detects double-stranded RNA (ds-RNA) common to viruses
[113–116]. Both intracellular and extracellular expression of TLR3 has
beendetected inhuman astrocytes andupregulation canbe triggeredby
IFN-γ or IL1-β [113]. PolyI:C stimulation,which syntheticallymimicsds-
RNA, induces upregulation of TLR2-4 in vitro as well as several growth
and neuroprotective factors [115,117,118]. Astrocytes also express a
number of other pattern recognition receptors [119]. TMEV infection
induces an array of cytokine and chemokine secretion via TLR3
activation [120]. Interestingly, TLR3 activation plays a major role in
the astrocytic response to polyI:C but not TMEV infection; conversely
ds-RNA-dependent protein kinase PKR is more important for respond-
ing to TMEV, but not polyI:C stimulation [121]. These data imply
differentmechanisms in astrocytic responses to viral stimuli,whichmay
be important for understanding the induction andprogression in TMEV-
IDD and MS.
4.2. Cytokine production
Whether or not astrocytes are successful at presenting antigen to T
cells during MS, they can provide an environment that promotes T cell
activation. Astrocytes are capable of producing IL-12 (Th1), IL-4 (Th2),
IL-23 (Th17), IL-6 and TGF-β (Th17), each of which can drive naïve T
cells into a different T cell subtype in the presence of antigen
presentation [122]. However, it is currently unknown what impact
astrocytic-produced cytokines have on T cell differentiation during MS.
4.3. T cell recruitment
Although astrocytes areweak APCs, they serve an important role in
regulation and T cell recruitment by producing potent levels of
cytokines and chemokines. Astrocyte processes surround blood vessel
endothelial cells, making astrocytes major players in recruiting
leukocytes from the periphery. Inﬂammation induces astrocytes to
produce cytokines that increase the blood brain barrier permeability,
allowing easier inﬁltration by leukocytes [119]. In response to IFN-γ,
TNF-α, and TMEV infection astrocytes upregulate ICAM-1 and VCAM-
1 adhesion molecules which aids in leukocyte recruitment [123–125].
In response to IL-17, astrocytes produce CCL2, CCL12, CXCL1, and
CXCL2, a distinctly different proﬁle compared to IFN-γ stimulation
[13,60]. Human and murine astrocytes also recruit monocytes and T
cells by producing signiﬁcant amounts of CCL2, CCL5, and CXCL10 in
response to TMEV infection and polyI:C stimulation [113,115,126].
Astrocytes produce CCL2 during multiple phases of EAE as well [127].
Interestingly, TNF-α and IL-1β stimulate astrocytes to secrete
chemokines that attract immature, but not mature, DCs. [128] Thus,
astrocytes could potentially be recruiting more effective APCs into an
environment full of myelin debris, at the same time myelin-speciﬁc T
cells requiring re-stimulation are recruited, further propagating
disease. Kang et al. recently determined that EAE disease progression
was inhibited and leukocytes were not recruited in a nestin-speciﬁc
(astrocytes, neurons, oligodendrocytes) knockout of act1, an impor-
tant protein in the IL-17R signaling complex [13]. They suggested that
astrocytes were most likely the cellular compartment responsible for
recruiting leukocytes based on their act1-dependent chemokine
production in response to IL-17 in vitro. These data imply that
astrocytes are necessary for disease progression in Th17-mediated
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tion is necessary to determine whether responses to IL-17 in
oligodendrocytes and neurons contribute to leukocyte recruitment.
4.4. MHC and co-stimulatory molecule expression
A number of studies have focused on characterizing the ability of
astrocytes to express MHC class I and II, and co-stimulatory molecules
under normal and inﬂammatory conditions to determine if they are
capable of presenting antigen to T cells [70,129–133]. MHC class II is
expressed in twoknownenvironments in humans:MS lesions [134] and
IFN-γ-stimulated astrocytes in vitro [135]. Murine astrocytes also
express very low levels of MHC class II but upregulate expression
upon IFN-γ stimulation [70,129,130,136]. TNF-α inhibits IFN-γ-induced
MHC class II upregulation without affecting the increased expression of
class II major histocompatibility complex transactivator (CIITA), a
transactivating protein necessary for MHC class II transcription [124].
For a reviewon CIITA regulation ofMHC class II expression in astrocytes,
see Dong and Beneviste 2001 [137]. IL-1α, TGF-β, and serotonin
receptor agonists also inhibit IFN-γ-induced MHC class II upregulation
in astrocytes [138–140]. As for MHC class I expression, astrocytes
normally express relatively low levels, but upregulate it in response to
viral infection, yet not as fast or robustly as microglia [131].
Co-stimulatory molecule expression is less straightforward. Two
groups have demonstrated that murine astrocytes constitutively
express CD86 at low levels, but upregulate CD80 and CD86 in response
to IFN-γ stimulation [129,141]. Soos et al. did not observe CD80
upregulation upon IFN-γ stimulation in cultured astrocytes, but noted a
correlation between T cell activation and astrocytic expression of CD80/
86 molecules [133]. Similarly, Aloisi et al. did not detect IFN-γ-induced
upregulation of CD80 or CD86 expression in vitro, but determined that
IFN-γ-stimulated astrocytes were still capable of inducing differentia-
tion of T cells into a Th2 phenotype [31]. However, IFN-γ-stimulated
murine astrocytes in vitromay not behave the same way during EAE or
MS. Indeed, astrocytes do not express CD80, CD86, or CD40 during EAE
[132,142]. Furthermore, researchers studying human astrocytes in vitro
reported no constitutive or IFN-γ-induced expression of CD80/86
molecules [53]. However, a more recent study established that
astrocytes in chronic MS lesions do express CD80 and CD86 [143].
Human fetal astrocytes upregulated CD40 expression in response to
TNF-α, IL-1β, IFN-γ and LPS in vitro [144]. Although expression of co-
stimulatory factors is necessary for successful T cell activation, the best
analysis of APC function is their interaction with T cells.
4.5. T cell priming
In TMEV-IDD, astrocytes have been reported to be the major CNS-
resident cell type responsible for viral persistence [145], indicating
that astrocytes must not successfully present antigen to CD8+ T cells
for efﬁcient viral clearance. However, there is convincing evidence
that virally infected astrocytes form both Kupfer and non-Kupfer
immunological synapses with CD8+ T cells in vivo and in vitro, induces
a polarizing morphological change uncommon to uninfected astro-
cytes [146–148]. Interestingly, there are differences in astrocytic
antigen presentation between murine strains. Unstimulated BALB/c,
but not C57Bl/6 astrocytes, was capable of stimulating CD8+ T cells in
vitro in a peptide dose-dependent way [129]. Yet TMEV-resistant
(C57Bl/6) astrocytes weremore efﬁcient in processing and presenting
viral antigen than TMEV-susceptible (SJL/J) astrocytes after TMEV
infection and IFN-γ stimulation in vitro [126]. Infected or stimulated
TMEV-resistant astrocytes had a higher upregulation of MHC class I,
vascular cell adhesion molecule 1 (VCAM-1), and intracellular cell
adhesion molecule 1 (ICAM-1) compared to TMEV-susceptible
astrocytes [126]. These differences between C57Bl/6 and SJL/J
astrocytes could potentially regulate susceptibility and resistance to
the development of demyelinating disease.In EAE, naïve T cells are ﬁrst introduced to myelin antigens in the
periphery, and are required to be reactivated upon entering the CNS
[14]. It is possible that astrocytes may be in part responsible for this
reactivation of myelin-speciﬁc T cells. Several studies have demonstrat-
ed that IFN-γ-stimulated astrocytes are capable of inducing Th1
differentiation and proliferation of naïve myelin-speciﬁc T cells
[114,130,133,149–151]. Interestingly, only PLP139–151 speciﬁc T cells
activated by IFN-γ-stimulated astrocytes induced EAE by adoptive
transfer andnot those T cells speciﬁc to subdominantPLPepitopes [130].
This data suggests that astrocytes may not be involved in epitope
spreading, but may play a role in the initial inﬂammatory response.
MBP-speciﬁc T cell proliferation induced by IFN-γ-stimulated astrocytes
was blocked by antibodies against IL-12/23 p40, indicating that
astrocytes are capable ofmaintainingactivatedTh1 andTh17 cells [149].
Astrocytes may not be as efﬁcient at priming T cells in vivo as these
data purport. For instance, IFN-γ-stimulated astrocytes expressing
human MHC (HLA-DR2 & 4) were efﬁcient in presenting MOG peptide
but not native protein, [150] signifying a deﬁciency in antigen
processing or peptide loading. Given the right pro-inﬂammatory
environment with available peptide, astrocytes are capable of priming
myelin-speciﬁc CD4+ and CD8+ T cells, but whether or not this speciﬁc
environment occurs during MS or EAE requires more investigation.
4.6. Regulation
Similar to professional APCs, astrocytes react to injury and
infections in a stimulus-speciﬁc way. Astrocytes are capable of
modifying the response of all other cell types in the CNS primarily
through the production of cytokines, making them powerful regula-
tors of both immune responses and repair. Astrocytes can both
enhance and down regulate the activation of microglia. For instance
astrocytic production of GM-CSF and macrophage colony stimulating
factor (M-CSF) is required for microglial antigen presentation,
whereas TGF-β production can down regulate microglial activation
andMHC class II expression [152–154]. During EAE andMS, astrocytes
produce immunosuppressive TGF-β and IL-10 [154]. Astrocytes also
contain inﬂammation by forming a physical barrier called a glial scar,
characterized bymorphological and gene expression changes induced
by inﬂammation [155]. Neurons are vulnerable during immune
responses, however astrocytes commonly upregulate neuroprotective
genes such as neurotrophin-4, ciliary neurotrophin factor, and nerve
growth factor after presenting antigen to MBP-speciﬁc Th1 and Th2
cells and in response to viral infections [118,151].
Peripheral immune responses are largely regulated by death
receptor-mediated cell death. Astrocytes constitutively express high
levels of Fas and FasL, however they are unusually resistant to death
receptor induced apoptosis, allowing them to regulate Fas-expressing
cells such as activated T cells while surviving most Fas-mediated
signals [156,157]. Fas signaling is cytotoxic to microglia, whereas
astrocytes survive and respond by producing inﬂammatory chemo-
kines [158]. Thus, astrocytes may be more important for regulating
inﬁltrating immune responses by attenuating inﬂammation.
Astrocytes are dynamic cells that are necessary for multiple
cellular processes in the CNS. They may be inefﬁcient at presenting
antigen, but they are resilient responders to inﬂammation, providing
both pro-inﬂammatory and protective regulatory responses.
5. Conclusions
The protection of the CNS via CNS-resident cells and inﬁltrating
immune cells is paramount for the survival and defense of an
individual. Regulation of these cells and their responses is important
for maintaining a homeostatic environment. However, under aberrant
conditions CNS inﬂammation can persist and lead to the chronic
development of autoimmunity. APCs within the CNS are critical for
host defense against pathogens, however they can contribute to a
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oligodendrocytes and myelin. Microglia have been demonstrated to
upregulate classical APC machinery (i.e. MHC class I and class II), as
well as secrete inﬂammatory cytokines such as TNF-α. Though they
are not the most numerous cell type within the CNS, their ability to
inﬂuence the immune response indicates their potency. Dendritic
cells, though not CNS-resident cells, are emerging as a key player in
the priming autoreactive T cells both within the periphery as well as
within the CNS. Additionally, they appear to be able to direct an
inﬂammatory Th17 type response, which is newly associated with
chronic autoimmune diseases such as MS. Astrocytes are the most
numerous cell type in the CNS and are crucial for maintaining BBB
integrity, however can be harmful via their ability to secrete
inﬂammatory chemokines directing the recruitment of inﬁltrating
immune cells that can mediate damage to oligodendrocytes and their
myelin. Future studies targeted at prevention of APC effector function
may lead to the development of effective therapies for limiting
chronic CNS inﬂammation and autoimmunity.
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